HIV DART and Emerging Viruses: Frontiers in Drug Development and Antiretroviral Therapies

HIV DART 和新兴病毒：药物开发和抗逆转录病毒疗法的前沿

• 批准号: 10059173
• 负责人: Raymond Felix Schinazi
• 金额: $ 2万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-11-13 至 2023-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10059173
• 关键词: Accreditation; Acquired Immunodeficiency Syndrome; Adherence; Americas; Antiviral Agents; Applications Grants; Area; Biology; Chemistry; Chikungunya fever; Childhood; Chronic; Clinical; Clinical Research; Communicable Diseases; Communities; Dengue Fever; Development; Disease; Disease remission; Drug Kinetics; Ebola; Educational workshop; Elderly; Ensure; Face; Formulation; Future; HIV; HIV Infections; Health Personnel; Health Professional; Health Services Accessibility; Hepatitis B; Hepatitis C virus; Individual; Inflammation; International; Knowledge; Learning; Life; Location; Medical; Methods; Nurses; Oral; Pharmaceutical Preparations; Pharmacology; Physicians; Population; Postdoctoral Fellow; Research Personnel; Retroviridae; Role; Scholarship; Scientist; Serology; System; Therapeutic; Therapeutic Agents; Time; Training; Treatment Protocols; United States; United States National Institutes of Health; Viral; Viral reservoir; Virus; Yellow Fever; antiretroviral therapy; co-infection; continuing medical education; design; drug development; drug metabolism; frontier; graduate student; improved; lectures; microbicide; neuroAIDS; novel; novel therapeutics; posters; programs; side effect; symposium; treatment as prevention; vaccine development; zika fever

Abstract/Project Summary Thanks to advances in antiretroviral therapy, the face of HIV and AIDS has been gradually and meaningfully transformed from a deadly disease, into a chronic condition that is managed with careful adherence to life-long treatment regimens. The need for improved drugs, with fewer side-effects, improved adherence and more favorable pharmacokinetics increases as the number of infected individuals on long-term therapy continues to rise. Importantly, the quest for an HIV cure continues to gain momentum as we learn more about viral reservoirs and mechanisms of viral persistence. HIV DART and Emerging Viruses is a biennial conference for physicians, clinicians, nurses, scientists and clinical researchers that will focus on the latest discoveries in these areas. Specific Aims: 1. Gather cross-disciplinary professionals such as clinicians, health care workers, researchers and basic scientists together in an interactive workshop setting to share and discuss the latest developments in the field of HIV and emerging viruses; 2. Facilitate the neutral and balanced exchange of scientific knowledge with regard to antiviral drug development, vaccine development, and recent progress in curative strategies; 3. Enhance the training of young scientists such as graduate students and post-doctoral fellows and provide increased opportunities for underrepresented scientists and health care workers through attendee scholarships. Educational Objectives: 1. Identify novel therapeutic agents and viral targets for HIV, retroviruses and other emerging viruses; 2. Understand HIV reservoirs and viral persistence; 3. Discuss novel remission, cure, and eradication strategies for HIV; 4. Discuss inflammation in the context of HIV infection, neuroAIDS and AIDS in geriatric and pediatric populations; 5. Understand drug metabolism and pharmacology and discuss improved formulations; 6. Discuss treatment access, treatment as prevention and the role of microbicides; 7. Discuss HIV treatment in the context of co-infection with Hepatitis B or hepatitis C virus; 8. Discuss recent advances in vaccine development and systems serology; 9. Discuss recent scientific discoveries with regard to emerging viral threats such as Ebola, Zika, chikungunya, dengue and yellow fever. Design & Methods: HIV DART and Emerging Viruses will take place in the United States of America over a 2.5 days period, at a location that is easily accessed by both national and international delegates. The program will include plenary lectures, oral abstract presentations, discussion panels and a debate. This ACCME-accredited program will provide ample time for formal and informal networking and discussion amongst the delegates during the poster session and meal breaks.

摘要/项目摘要 由于抗逆转录病毒疗法的进步，艾滋病毒和艾滋病的面貌已逐渐被人们所认识。 并有意义地从致命疾病转变为可控制的慢性病 认真遵守终身治疗方案。需要改进药物，减少药物用量 随着数量的增加，副作用、依从性提高和更有利的药代动力学 接受长期治疗的感染者人数持续上升。重要的是，寻找艾滋病毒 随着我们对病毒库和病毒机制的了解越来越多，治愈的势头继续增强 病毒的持续存在。 HIV DART 和新兴病毒是每两年一次的医生会议， 临床医生、护士、科学家和临床研究人员将重点关注以下方面的最新发现 这些领域。 具体目标： 1. 聚集临床医生、医疗保健等跨学科专业人士 工人、研究人员和基础科学家在互动研讨会环境中一起分享 并讨论艾滋病毒和新兴病毒领域的最新进展； 2. 促进 关于抗病毒药物的科学知识的中立和平衡的交流 开发、疫苗开发以及治疗策略的最新进展； 3. 增强 培养研究生、博士后等青年科学家，并提供 通过以下方式增加代表性不足的科学家和卫生保健工作者的机会 与会者奖学金。教育目标： 1. 识别新型治疗药物和病毒 HIV、逆转录病毒和其他新出现病毒的靶标； 2. 了解艾滋病毒储存库和病毒 坚持； 3. 讨论新的艾滋病毒缓解、治愈和根除策略； 4. 讨论 HIV 感染、神经艾滋病和老年和儿科艾滋病中的炎症 人口； 5. 了解药物代谢和药理并讨论改进 配方； 6. 讨论治疗途径、治疗即预防以及杀菌剂的作用； 7. 讨论合并感染乙型肝炎或丙型肝炎病毒时的艾滋病毒治疗； 8. 讨论疫苗开发和系统血清学的最新进展； 9.讨论最近的事情 关于埃博拉、寨卡、基孔肯雅热等新兴病毒威胁的科学发现 登革热和黄热病。设计和方法：HIV DART 和新兴病毒将在 在 2.5 天的时间里，在双方都可以轻松到达的地点前往美利坚合众国 国家和国际代表。该计划将包括全体演讲、口头摘要 演讲、讨论小组和辩论。这个 ACCME 认证的项目将提供 会议期间，代表们有充足的时间进行正式和非正式的交流和讨论 海报会议和用餐时间。